Early access
Sign in
Not yet taking people in SwedenPhase 3

Tests glutamate infusion to prevent kidney injury after heart bypass surgery

Tests glutamate given through a vein to prevent kidney injury in adults without diabetes.

Key facts

Who runs it
Region Oestergoetland
Where
Goteborg, Linkoping, Lund, Orebro, and Uppsala, SwedenSee the 5 sites
Registry title
GLUTAMICS III
Status
Not yet recruiting
Phase
Phase 3
People taking part
380 people, planned
Starts
1 Oct 2027
Expected to end
31 Dec 2030
Type of study
Interventional
Record updated
4 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults without diabetes who are having heart bypass surgery (CABG) with a heart-lung machine and who have a high risk of kidney injury afterwards.

Age
18 years or older, up to 85 years.
Sex
All sexes can join.
Disease stage
Coronary artery disease affecting at least two vessels or the left main artery. High risk means EuroSCORE II of 3.0 or more plus at least one cardiac or procedure-related risk factor, or a heart pumping fraction (Left Ventricular Ejection Fraction) of 0.30 or less.
Earlier treatment
No previous heart surgery.

Main reasons for not taking part

  • Diabetes
  • Previous heart surgery
  • Dialysis before surgery or creatinine clearance below 30 mL/min
  • Needing medicines or a device to support the heart before surgery
  • Surgery without a heart-lung machine (off-pump)

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Adult patients without diabetes operated on heart-lung machine with CABG of at least two vessel disease or left main stenosis with or without a concomitant procedure and who either have EuroSCORE II ≥ 3.0 to which at least one cardiac or procedure related risk factor contribute or Left Ventricular Ejection Fraction ≤ 0.30 regardless of EuroSCORE II

Who cannot take part

  • Diabetes; ambiguous food allergy known to have elicited flushing, headache, rash or asthma; age > 85 years; previous cardiac surgery; informed consent not possible because of critical condition or other reason; preoperative use of inotropic support or mechanical circulatory assist; preoperative dialysis or calculated Creatinine clearance < 30 mL/min; surgery without heart-lung machine (off-pump); concomitant Maze-procedure; surgery of ascending aorta necessitating circulatory arrest; surgery of both aortic and mitral valve

Where in Sweden

  • Sahlgrenska University Hospital-Vaestra GoetalandsregionenGoteborg, SwedenNot yet recruiting
  • Region OestergoetlandLinkoping, SwedenNot yet recruiting
  • Region Skane Skanes UniversitetssjukhusLund, SwedenNot yet recruiting
  • Region Oerebro LaenOrebro, SwedenNot yet recruiting
  • Uppsala University HospitalUppsala, SwedenNot yet recruiting

About the trial

What the trial wants to find out

To establish the efficacy of intravenous glutamate infusion to prevent acute kidney injury (AKI) after coronary artery bypass surgery (CABG) among high-risk patients without diabetes.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Glutamate infusion for prevention of Acute Kidney Injury in surgery for ischemic heart disease: (GLUTAMICS III = GLUTAmate for Metabolic Intervention in Coronary Surgery III)
Plain-language title
Tests glutamate infusion to prevent kidney injury after heart bypass surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
4 June 2026